| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EAF1 |
| Uniprot No | Q96JC9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 182-268aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSDIIEQMS SSSGSSSSDS ESSSGSDDDS SSSGGEDNGP ASPPQPSHQQ PYNSRPAVAN GTSRPQGSNQ LMNTLRNDLQ LSESGSDSDD |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EAF1重组蛋白的模拟参考文献(基于领域知识构建，供参考)：
1. **文献名称**：*"Recombinant EAF1 interacts with ELL and regulates RNA polymerase II transcription elongation"*
**作者**：Smith J, et al.
**摘要**：研究通过大肠杆菌表达系统成功纯化重组EAF1蛋白，并证明其与转录延伸因子ELL结合，共同调控RNA聚合酶II的转录延伸活性，揭示了EAF1在基因表达中的关键作用。
2. **文献名称**：*"Structural and functional analysis of the EAF1-U19 domain using recombinant protein technology"*
**作者**：Zhang Y, et al.
**摘要**：利用昆虫细胞表达系统制备重组EAF1蛋白，结合X射线晶体学解析其U19结构域的三维构象，发现该区域对EAF1与染色质修饰复合物的结合至关重要。
3. **文献名称**：*"Recombinant EAF1 enhances DNA repair efficiency by stabilizing BRCA1-BARD1 complex"*
**作者**：Li H, et al.
**摘要**：通过体外实验证实，重组EAF1蛋白能够促进BRCA1-BARD1复合物的稳定性，增强同源重组修复能力，为EAF1在癌症基因组稳定性中的功能提供新证据。
4. **文献名称**：*"Optimization of EAF1 recombinant protein expression in mammalian cells for therapeutic screening"*
**作者**：Wang R, et al.
**摘要**：开发了一种高效哺乳动物细胞表达体系，用于生产高纯度重组EAF1蛋白，并验证其在药物筛选中的应用潜力，为靶向EAF1的抗癌疗法奠定基础。
**注**：以上文献为示例性质，如需真实文献建议通过PubMed/Google Scholar以关键词“EAF1 recombinant protein”或“EAF1 expression and function”检索。
EAF1 (ELL-associated factor 1) is a transcriptional regulatory protein that plays a critical role in modulating RNA polymerase II-mediated transcription elongation. It was initially identified as a binding partner of ELL (eleven-nineteen leukemia), a RNA Pol II elongation factor implicated in chromosomal translocations associated with acute myeloid leukemia. EAF1 forms a stable complex with ELL and other elongation factors, contributing to the stabilization of transcriptional machinery and prevention of premature termination during mRNA synthesis. This interaction highlights its involvement in maintaining transcriptional fidelity and regulating gene expression at the elongation stage.
Beyond its canonical role in transcription, EAF1 has been linked to chromatin modification through associations with histone acetyltransferases, suggesting a broader impact on epigenetic regulation. Studies also implicate EAF1 in cellular processes such as apoptosis, cell cycle control, and DNA damage response, though these mechanisms remain under investigation. Its dysregulation has been observed in certain cancers, particularly leukemias involving MLL-ELL fusion proteins, making it a potential biomarker or therapeutic target.
Recombinant EAF1 protein, typically expressed in bacterial or eukaryotic systems, serves as a vital tool for structural studies (e.g., crystallography), biochemical assays to map protein-protein/DNA interactions, and functional analyses of transcriptional complexes. Purified EAF1 enables researchers to dissect its molecular partnerships within elongation complexes and evaluate its regulatory crosstalk with pathways like p53 signaling. Ongoing research focuses on elucidating its post-translational modifications and context-specific roles in both normal physiology and disease states, particularly hematological malignancies.
×
